Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies. The company operates within the biotechnology and pharmaceutical industry, targeting rare disorders where approved therapies are limited or absent. The filing does not disclose overall market size or growth rate for the industry, but it notes that aSAH accounts for about 5% of all strokes with an estimated 42,500 U.S. hospital treated patients per year, and that company-sponsored research suggests incidence may be as high as approximately 70,000 in the United States. Outside the U.S., annual aSAH cases are estimated at approximately 60,000 in the European Union and approximately 150,000 in China. The company believes rare disorders represent an attractive area for drug development, and a key advantage is the potential to receive orphan drug designation from the FDA.

The company's competitive positioning is built on a pipeline of three clinical-stage drug candidates supported by an intellectual property portfolio of more than 79 granted and pending patents in various jurisdictions worldwide, including 10 U.S. issued patents and 3 pending U.S. patent applications. The filing names no specific competitors but acknowledges that the biopharmaceutical industry is intensely competitive and that many competitors have substantially greater financial, technical, and other resources. The company's stated competitive advantages include its novel drug delivery technologies, the use of the Section 505(b)(2) regulatory pathway for potentially shorter paths to approval, orphan drug designations for all three candidates, and a management team with significant experience in drug formulation, drug delivery research and development, manufacturing, regulatory affairs, business development, and late-stage drug development and commercialization.

The company generates revenue through the development and potential commercialization of pharmaceutical products for rare and orphan diseases. As of the filing date, the company has not yet received FDA approval for any drug candidate and has not generated any product revenue. The business model relies on applying new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery, and increased patient compliance. The company plans to commercialize GTx-104 in the U.S. with a highly experienced and targeted hospital-based sales force if approved, and may seek commercial partnerships for territories outside the U.S. For GTx-102 and GTx-101, the company does not plan to resume internal development funding and instead seeks to maximize value through out-licensing or sale.

The company's lead drug candidate is GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules. The pivotal Phase 3 STRIVE-ON randomized safety trial enrolled 50 patients administered GTx-104 and 52 patients receiving nimodipine oral capsules. The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compared to nimodipine oral capsules (28% versus 35%). 54% of patients who received GTx-104 had a relative dose intensity of 95% or higher of the prescribed dose compared to only 8% on nimodipine oral capsules. There was a 29% relative increase in the number of patients receiving GTx-104 compared to nimodipine oral capsules with favorable outcomes at 90 days follow up on the modified Rankin scale. The bioavailability of nimodipine oral capsules observed was only approximately 7% compared to 100% for GTx-104. The company submitted an NDA to the FDA in June 2025, which was accepted for review in August 2025 with an April 23, 2026 PDUFA target date. In April 2026, the FDA issued a Complete Response Letter citing certain items in the CMC and non-clinical sections, including additional leachable data time points for commercial product, non-clinical product toxicology risk assessments, and cGMP deficiencies at the company's CMO. The CRL did not raise any issues with respect to the safety or efficacy of GTx-104. A Type A meeting with the FDA has been scheduled.

GTx-102 is a novel, concentrated oral-mucosal spray of betamethasone intended to improve neurological symptoms of Ataxia Telangiectasia, for which there are currently no FDA-approved therapies. A-T affects approximately 4,300 patients per year in the United States and has a potential total addressable market of $150 million. A Phase-1 pharmacokinetic study was successfully completed and GTx-102 was well tolerated with no serious events reported. As of March 31, 2026, the remaining capitalized carrying value of GTx-102 was $9.2 million. GTx-101 is a non-narcotic, topical bio-adhesive film-forming bupivacaine spray for Postherpetic Neuralgia. PHN affects approximately 120,000 patients per year in the United States, and the total addressable market for GTx-101 could be as large as $2.5 billion, consisting of approximately $200 million for PHN pain and $2.3 billion for non-PHN pain indications. Four single-dose Phase 1 trials have been performed, and no serious adverse events were reported. As of March 31, 2026, the remaining capitalized carrying value of GTx-101 was $4.3 million. In June 2026, the company decided not to resume internal development funding for GTx-102 or GTx-101 under its current operating plan, and expects to recognize an impairment charge for the full remaining carrying values of both assets in the first quarter of fiscal year 2027.

In May 2023, the company implemented a strategic realignment plan that resulted in engaging a new management team, streamlining research and development activities, and greatly reducing the workforce. Following the realignment, the company concentrated on the development of GTx-104. In February 2025, the company completed a private placement of securities with certain institutional and accredited investors, with net proceeds of $13,705. In September 2023, the company completed a separate private placement with net proceeds of $7,338. In October 2025, the company received $4,040 in net proceeds from exercises of 1,345,464 2023 Common Warrants. The remaining 1,190,927 2023 Common Warrants expired on October 21, 2025. In June 2026, the company determined it will not resume internal development funding for GTx-102 or GTx-101 under its current operating plan. The company retains all intellectual property and patent rights associated with GTx-102 and GTx-101 and continues to evaluate business development opportunities, including out-licensing, partnerships, or non-dilutive arrangements.

For the fiscal year ended March 31, 2026, the company reported a net loss of $7,793, or $0.47 loss per share, compared to a net loss of $9,568, or $0.79 loss per share, for the prior fiscal year. Research and development expenses decreased by $7,106 to $2,405, primarily due to the close-out of the GTx-104 pivotal Phase 3 safety clinical trial. General and administrative expenses increased by $1,504 to $8,672, driven by non-recurring legal and due diligence costs and pre-commercial planning for GTx-104. Cash and cash equivalents were $16,977 as of March 31, 2026, compared to $22,133 as of March 31, 2025. The company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of the consolidated financial statements.

Management states that it expects to provide a regulatory update after the receipt of official meeting minutes from the Type A meeting with the FDA scheduled to potentially clarify the path forward for GTx-104. The company expects to recognize an impairment charge for the full remaining carrying value of GTx-102 of $9.2 million and GTx-101 of $4.3 million in the first quarter of fiscal year 2027.

The primary growth vector for the company is the advancement of GTx-104 toward regulatory approval and commercialization. The company believes that GTx-104 has the potential to address significant challenges with oral nimodipine administration and may transform the standard of care for patients with aSAH. The market opportunity for GTx-104 is estimated at approximately 42,500 patients in the United States per year, with company-sponsored research suggesting incidence may be as high as approximately 70,000 in the United States. Outside of the United States, annual cases of aSAH are estimated at approximately 60,000 in the European Union and approximately 150,000 in China. In an independent market research survey, respondents reported 80% likelihood of adopting an IV formulation of nimodipine. The company plans to commercialize GTx-104 in the U.S. with a highly experienced and targeted hospital-based sales force if approved, and may seek commercial partnerships for territories outside the U.S.

The company is also pursuing value maximization from its de-prioritized drug candidates, GTx-102 and GTx-101, through potential out-licensing or sale. For GTx-102, the company notes that A-T affects approximately 4,300 patients per year in the United States and has a potential total addressable market of $150 million. For GTx-101, the total addressable market could be as large as $2.5 billion, consisting of approximately $200 million for PHN pain and $2.3 billion for non-PHN pain indications. The company retains all intellectual property and patent rights associated with both candidates and continues to evaluate business development opportunities, though there can be no assurance that any such transaction will be completed on favorable terms or at all.

The filing does not provide specific margin or cost outlook targets. Research and development expenses decreased significantly from $9,511 in fiscal 2025 to $2,405 in fiscal 2026, primarily due to the completion of the GTx-104 pivotal Phase 3 trial. General and administrative expenses increased from $7,168 to $8,672, driven by non-recurring legal and due diligence costs and pre-commercial planning for GTx-104. The company expects expenses to increase substantially in connection with ongoing activities, particularly as it advances clinical development, engages contract manufacturing organizations, seeks regulatory approval, and adds personnel to support future product launch and commercialization.

The company currently does not own any manufacturing facilities and relies on a network of third-party CMOs for manufacturing its drug candidates. All CMOs are monitored and evaluated to assess compliance with regulatory requirements. The company works with independent consultants to perform periodic quality audits of its manufacturers. In April 2026, the company received a CRL from the FDA identifying certain cGMP deficiencies at its current CMO for GTx-104. The company's ability to obtain regulatory approval for GTx-104 is dependent, in significant part, on its CMO's ability to timely and satisfactorily remediate the identified deficiencies. As of March 31, 2026, the company had a total of five full-time employees, all located in the United States.The company states it will require additional capital to fund daily operating needs beyond the 12-month period from the issuance date of the financial statements. The company plans to raise additional capital primarily through additional securities offerings and multiple sources of non-dilutive capital, such as grants, loans, and strategic alliances. The company does not anticipate paying any cash dividends on its common stock for the foreseeable future. The company's orphan drug designation for GTx-104 can result in tax credits of up to 25% of clinical development costs conducted in the United States upon marketing approval and a waiver of the NDA fees, which the company estimates can translate into savings of approximately $4.3 million for GTx-104.

The company faces a significant headwind from the Complete Response Letter received from the FDA in April 2026 for GTx-104, which cited manufacturing deficiencies and other non-clinical issues that may delay or prevent approval. The company relies in large part on its CMO to remediate the identified deficiencies, and remediation may require facility upgrades, quality system enhancements, equipment requalification, and additional validation studies or testing, any of which could be costly and time-consuming. If the CMO is unable to adequately or timely remediate the deficiencies, the company may need to transfer manufacturing operations to an alternative facility, which would involve significant time, expense, and regulatory risk. The company also faces uncertainty relating to healthcare reform measures and reimbursement policies that could hinder or prevent commercial success.

The company has identified several structural headwinds and execution risks. The company is heavily dependent on the success of GTx-104, and failure to obtain approval would adversely affect its business, financial condition, and prospects. The company has no history of commercializing drugs, which may make it difficult to assess future viability. The company may not be able to maintain operations and advance research and development without additional funding. Unfavorable global geopolitical events and economic conditions, including military conflicts and trade tensions, could adversely affect the business. The company may not be able to maximize value from its de-prioritized drug candidates, GTx-102 and GTx-101, through out-licensing or sale.

The most material risk is the Complete Response Letter received from the FDA in April 2026 for GTx-104, which cited manufacturing deficiencies and other non-clinical issues that may delay or prevent approval. The company relies on its CMO to remediate cGMP deficiencies, and if the CMO is unable to do so, the company may need to transfer manufacturing to an alternative facility, resulting in significant delays, increased costs, or inability to obtain regulatory approval. The company is heavily dependent on the success of GTx-104, and failure to obtain approval would materially and adversely affect its business. The company had cash and cash equivalents of $17.0 million as of March 31, 2026, and believes additional capital will be required to support the commercial launch of GTx-104 if approved. The company has no history of commercializing drugs, which may make it difficult to assess future viability. The company may not be able to maximize value from its de-prioritized drug candidates, GTx-102 and GTx-101, through out-licensing or sale. The company faces significant competition from other biotechnology and pharmaceutical companies with substantially greater resources.

Management's message emphasizes the company's focus on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, with a primary concentration on GTx-104. Management highlights that the Phase 3 STRIVE-ON trial met its primary endpoint and provided evidence of clinical benefit for GTx-104 compared to nimodipine oral capsules, including a 19% reduction in clinically significant hypotension, a 54% rate of patients achieving 95% or higher relative dose intensity versus 8% on oral capsules, and a 29% relative increase in favorable outcomes at 90 days. Management acknowledges the receipt of the Complete Response Letter from the FDA in April 2026 and states that a Type A meeting has been scheduled to potentially clarify the path forward. Management expects to provide a regulatory update after the receipt of official meeting minutes. The strategic priorities emphasized for the period ahead include addressing the items referenced in the CRL for GTx-104, resubmitting the NDA, and continuing to evaluate business development opportunities for GTx-102 and GTx-101, including potential licensing or sale. Management states that the company retains all intellectual property and patent rights associated with GTx-102 and GTx-101 and continues to believe these programs may provide significant value through such transactions.